Archaeologists in Egypt have fully uncovered the ‘Lost City of Gold,’ a 3,000-year-old gold mining hub resurrected from the desert after four years of meticulous excavation. Found beneath ...

An archaeology breakthrough has discovered that humans inhabited rainforests around 150,000 years ago, a staggering 80,000 years earlier than previously believed. This revelation comes from an ...

The North Chicago, Ill., biopharmaceutical company said the European Commission, which generally follows the CHMP's advice, is expected to make a final decision in the first half of the year.

Current Archaeology Live! 2025 took place on 1 March 2025 at University College London’s Institute of Education, and where 600 of you joined us to hear the latest news on important discoveries and ...

The European Commission (EC) will now review the CHMP recommendation, and a decision on the label extension application of IXCHIQ ® in the European Union (EU), Norway, Liechtenstein and Iceland ...

The European Commission (EC) will now review the CHMP recommendation, and a decision on the label extension application of IXCHIQ ® in the European Union (EU), Norway, Liechtenstein and Iceland is ...

The commission last month asked the CHMP to consider whether the new information would require an update of the positive opinion, and to consider whether the wording of the risk minimization ...

The Indianapolis drugmaker said the European Commission, which generally follows the CHMP's advice, is expected to make a final decision in the next one to two months. Eli Lilly previously won ...

STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP ...

Therefore, this positive CHMP opinion marks a crucial milestone toward introducing a more robust preventative solution against chikungunya in the EU. Broader accessibility will help provide ...

The CHMP has specifically backed Leqembi to treat mild cognitive impairment or mild dementia from Alzheimer’s but only for patients carrying one or no copy of the ApoE4 gene.